


Be a Leading Country in Global Drug Discovery

July 30, 2024

Japan Pharmaceutical Manufacturers Association

Hiroaki Ueno, Ph.D.

Contribution of Pharmaceutical Industry to the Society as a Key Industry



The key is to continue movements toward strengthening the drug discovery eco-system as national strategy

Pharmaceutical Industry Initiatives to Strengthen Drug Discovery Eco-system

Industry group

Common initiatives to promote drug discovery activities

Each company

Open innovation activities based on each company's strategies

Initiatives by JPMA

Collaboration in non-competitive areas for sustainable innovation creation



- **Industry-academia-government collaboration**

Industry-academia consortium leveraging the strengths of academia research, etc.

- **Provide an industrial perspective**

A mechanism to provide knowledge to academic researchers (AMED-FLuX), etc.

- **Human resources development**

For biostatistics, biopharmaceutical manufacturing (BCRET), etc.

Recommendations and proposals towards government industrial policies



- **Drug pricing, pharmaceutical affairs**

FY 2024 Drug Price Revision, the Pharmaceutical Affairs Committee^{*1}, etc.

- **Drug discovery capabilities, industrial policy**

The drug discovery capability concept meeting^{*2}, headquarters for healthcare policy, etc.

^{*1}: https://www.mhlw.go.jp/stf/shingi/other-iyaku_128701_00006.html ^{*2}: <https://www.cas.go.jp/jp/seisaku/souyakuryoku/index.html>

Expectation for "the Public-Private Council"

Constructive and deep discussions from the following perspectives in order to strengthen global drug discovery capabilities in Japan

Consistency

Continuity

Integration

- Consistent and continuous policies are necessary

Basic Research

Non-Clinical Clinical trial Pharmaceutical Affairs Insurance listing

Drug

Long R&D period : 9-16 years

Low probability : (from Clinical) approx. 10%*

*from phase1 to launch

Support for drug development in each ministry

MEXT

METI

MHLW

Basic Research

- Integrated utilization by each ministry's programs
- Budget across multiple years

Drug

JPMA will contribute the discussion in "the Public-Private Council"